High-Dose Vitamin C for Neuropathy
High-dose vitamin C is NOT recommended as a standard treatment for neuropathy and may actually be harmful in certain contexts, particularly in patients receiving bortezomib chemotherapy where it can reduce drug efficacy. 1
Evidence-Based First-Line Treatments
The established pharmacological treatments for neuropathic pain are well-defined by multiple guidelines and should be prioritized:
Primary Recommendations
For diabetic peripheral neuropathy and general neuropathic pain, use gabapentinoids (pregabalin 300-600 mg/day or gabapentin 900-3600 mg/day), serotonin-norepinephrine reuptake inhibitors (duloxetine 60-120 mg/day), or tricyclic antidepressants (amitriptyline 25-75 mg/day) as first-line agents. 2, 3, 4
These medications have FDA approval (duloxetine and pregabalin specifically for diabetic neuropathy) and demonstrated efficacy with number-needed-to-treat values of 4-6 for achieving 50% pain reduction 2.
Vitamin C: Limited and Context-Specific Evidence
Where Vitamin C Shows Some Promise
The evidence for vitamin C in neuropathy is restricted to very specific contexts:
Postherpetic neuralgia: Intravenous vitamin C (7.5-15g every other day) showed benefit in small studies for spontaneous pain but NOT for brush-evoked pain 5, 6. Plasma vitamin C levels were significantly lower in these patients 6.
Complex regional pain syndrome: Some evidence suggests vitamin C may reduce CRPS risk in orthopedic contexts, though this is for prevention rather than treatment of established neuropathy 7.
Chemotherapy-induced neuropathy (cisplatin): Animal studies showed protective effects at 500 mg/kg/day, but human evidence is lacking 8.
Critical Warnings and Contraindications
Do NOT use high-dose vitamin C in patients receiving bortezomib chemotherapy for multiple myeloma, as it may interfere with drug metabolism and reduce efficacy. 1 The guideline explicitly states: "The use of high doses of vitamin C is also not recommended since it may interfere with the metabolism of bortezomib and reduce its efficacy."
Safety Considerations for High-Dose Use
When vitamin C doses exceed 6 g/day intravenously, monitor for:
- Oxalate nephropathy (5 reported cases in systematic review) 9
- Hypernatremia (5 cases) 9
- Hemolysis in G6PD deficiency patients (3 cases) 9
- Glucometer errors (falsely elevated readings) 9
- Kidney stones 9
High doses of pyridoxine (vitamin B6) can cause sensory neuron damage, especially with renal insufficiency 1, so combination vitamin supplementation requires caution.
Practical Algorithm
Step 1: Identify Neuropathy Type
- Diabetic peripheral neuropathy → Use duloxetine or pregabalin first-line 3
- Postherpetic neuralgia → Consider IV vitamin C (15g every 2 days for 2 weeks) ONLY if standard treatments fail 5
- Chemotherapy-induced → Avoid vitamin C if on bortezomib; use pregabalin/gabapentin 1
Step 2: Optimize Disease-Modifying Factors
- Tight glycemic control (HbA1c 6-7%) for diabetic neuropathy 2, 3
- Blood pressure and lipid control 3
- Address cardiovascular risk factors 2
Step 3: Pharmacologic Management
Start with ONE of these proven agents:
- Pregabalin: 150 mg/day, titrate to 300-600 mg/day (NNT 4.04 at 600mg) 2
- Duloxetine: 60-120 mg/day (NNT 4.9-5.2) 2
- Gabapentin: 900-3600 mg/day 2
- Tricyclic antidepressants: Start 10 mg/day, titrate to 25-75 mg/day (NNT 1.5-3.5, but avoid >100 mg/day due to cardiac risk) 2
Step 4: If Inadequate Response
- Add a second first-line agent from different class 4
- Consider tramadol 200-400 mg/day or other opioids for breakthrough pain 2
- Topical capsaicin 0.075% for localized pain 2
Bottom Line on Vitamin C
Vitamin C supplementation at standard doses (200-500 mg/day) is safe for patients with chronic oxidative stress or malabsorption 10, but there is no compelling evidence to recommend high-dose vitamin C as a routine treatment for neuropathy. The evidence is limited to small studies in postherpetic neuralgia using intravenous administration, and oral high-dose supplementation lacks robust clinical trial support for neuropathy treatment 7.
Use proven first-line agents with established efficacy and safety profiles rather than experimental vitamin C therapy, except in the specific context of refractory postherpetic neuralgia where IV administration may be considered as adjunctive therapy.